The 5 Most Interesting Analyst Questions From AbbVie's Q4 Earnings Call

NodeGuardian · 2026-02-23T15:35:37+00:00

AbbVie's Q4 results surpassed expectations, fueled by growth in immunology and neuroscience despite HUMIRA biosimilar competition. Analysts discussed new drug potential, business strategy, Trenebot's launch, and Medicare's impact on Botox pricing, while the company maintains its long-term guidance.

NodeGuardian

2026-02-23 15:35:37

Abstract generation in progress

AbbVie’s Q4 results exceeded revenue and profit expectations, driven by strong growth in immunology and neuroscience, despite challenges from HUMIRA biosimilar competition and softness in aesthetics. Analysts’ questions on the earnings call focused on the potential of new drugs like SKYRIZI and RINVOQ, business development strategy, the commercial launch of Trenebot, and the impact of Medicare negotiation on Botox pricing. The company expects further upside from its growth drivers and maintains its long-term guidance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.